CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis

Abstract excerpt

Abstract The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8 + T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, a classically described mechanism of tumor immune escape is tumor MHC-I downregulation. Here, we report that CD8 + T cells maintain the capacity to...

Topics

Join the communities discussing this publication.

• CAR-T cell therapy research
• Immune Cell Function and Interaction
• T-cell and B-cell Immunology